[{"address1": "41 Ninth Avenue", "address2": "14th Floor", "city": "New York", "state": "NY", "zip": "10001", "country": "United States", "phone": "646 661 7661", "fax": "646 661 4027", "website": "https://www.ovidrx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 40, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.", "age": 70, "title": "CEO & Chairman", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 1030026, "exercisedValue": 0, "unexercisedValue": 671250}, {"maxAge": 1, "name": "Mr. Jeffrey A. Rona", "age": 55, "title": "Chief Business and Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 761235, "exercisedValue": 0, "unexercisedValue": 104909}, {"maxAge": 1, "name": "Ms. Meg  Alexander", "title": "President & COO", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dirk  Haasner", "age": 58, "title": "Senior Vice President of Global Manufacturing & CMC QA", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 416952, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julia  Tsai Ph.D.", "age": 48, "title": "Senior Vice President of Clinical Development", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Toshiya  Nishi D.V.M.", "title": "Head of Epilepsy Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zhong  Zhong Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tom  Parry", "title": "Vice President of Research and Early Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1730073600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.19, "open": 1.21, "dayLow": 1.15, "dayHigh": 1.21, "regularMarketPreviousClose": 1.19, "regularMarketOpen": 1.21, "regularMarketDayLow": 1.15, "regularMarketDayHigh": 1.21, "beta": 0.386, "forwardPE": -2.948718, "volume": 95344, "regularMarketVolume": 95344, "averageVolume": 167210, "averageVolume10days": 109810, "averageDailyVolume10Day": 109810, "bid": 1.12, "ask": 1.21, "bidSize": 100, "askSize": 100, "marketCap": 83728048, "fiftyTwoWeekLow": 0.68, "fiftyTwoWeekHigh": 4.1, "priceToSalesTrailing12Months": 147.48773, "fiftyDayAverage": 1.154, "twoHundredDayAverage": 2.201605, "currency": "USD", "enterpriseValue": 20033314, "floatShares": 46486383, "sharesOutstanding": 70971600, "sharesShort": 606846, "sharesShortPriorMonth": 653891, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0086, "heldPercentInsiders": 0.15908, "heldPercentInstitutions": 0.56963, "shortRatio": 5.01, "shortPercentOfFloat": 0.0104, "bookValue": 1.253, "priceToBook": 0.91779727, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -29747960, "trailingEps": -0.41, "forwardEps": -0.39, "enterpriseToRevenue": 35.289, "enterpriseToEbitda": -0.305, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "OVID", "underlyingSymbol": "OVID", "shortName": "Ovid Therapeutics Inc.", "longName": "Ovid Therapeutics Inc.", "firstTradeDateEpochUtc": 1493991000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "51982f47-ea34-3602-8b3b-2a8cb7696156", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.15, "targetHighPrice": 5.0, "targetLowPrice": 1.3, "targetMeanPrice": 3.26, "targetMedianPrice": 3.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 76974000, "totalCashPerShare": 1.085, "ebitda": -65781180, "totalDebt": 15390000, "quickRatio": 5.452, "currentRatio": 5.729, "totalRevenue": 567695, "debtToEquity": 17.311, "revenuePerShare": 0.008, "returnOnAssets": -0.32612, "returnOnEquity": -0.29806998, "freeCashflow": -27548466, "operatingCashflow": -52903924, "revenueGrowth": 1.253, "grossMargins": 1.0, "operatingMargins": -110.75149, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]